These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24400806)

  • 1. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
    Armani E; Amari G; Rizzi A; De Fanti R; Ghidini E; Capaldi C; Carzaniga L; Caruso P; Guala M; Peretto I; La Porta E; Bolzoni PT; Facchinetti F; Carnini C; Moretto N; Patacchini R; Bassani F; Cenacchi V; Volta R; Amadei F; Capacchi S; Delcanale M; Puccini P; Catinella S; Civelli M; Villetti G
    J Med Chem; 2014 Feb; 57(3):793-816. PubMed ID: 24400806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of
    Fontana E; Cenacchi V; Pivetti F; Pignatti A; Pazzi T; Bondanza L; Pazzi M
    J Labelled Comp Radiopharm; 2017 Oct; 60(12):577-585. PubMed ID: 28763109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
    Villetti G; Carnini C; Battipaglia L; Preynat L; Bolzoni PT; Bassani F; Caruso P; Bergamaschi M; Pisano AR; Puviani V; Stellari FF; Cenacchi V; Volta R; Bertacche V; Mileo V; Bagnacani V; Moretti E; Puccini P; Catinella S; Facchinetti F; Sala A; Civelli M
    J Pharmacol Exp Ther; 2015 Mar; 352(3):568-78. PubMed ID: 25576073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
    Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E
    J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
    Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
    Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist.
    Tannheimer SL; Sorensen EA; Cui ZH; Kim M; Patel L; Baker WR; Phillips GB; Wright CD; Salmon M
    J Pharmacol Exp Ther; 2014 Apr; 349(1):85-93. PubMed ID: 24513870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents.
    Barberot C; Moniot A; Allart-Simon I; Malleret L; Yegorova T; Laronze-Cochard M; Bentaher A; Médebielle M; Bouillon JP; Hénon E; Sapi J; Velard F; Gérard S
    Eur J Med Chem; 2018 Feb; 146():139-146. PubMed ID: 29407945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.
    McKew JC; Lee KL; Shen MW; Thakker P; Foley MA; Behnke ML; Hu B; Sum FW; Tam S; Hu Y; Chen L; Kirincich SJ; Michalak R; Thomason J; Ipek M; Wu K; Wooder L; Ramarao MK; Murphy EA; Goodwin DG; Albert L; Xu X; Donahue F; Ku MS; Keith J; Nickerson-Nutter CL; Abraham WM; Williams C; Hegen M; Clark JD
    J Med Chem; 2008 Jun; 51(12):3388-413. PubMed ID: 18498150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity.
    Ochiai K; Ando N; Iwase K; Kishi T; Fukuchi K; Ohinata A; Zushi H; Yasue T; Adams DR; Kohno Y
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5451-6. PubMed ID: 21764304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel (S)-(+)-decursin derivative, (S)-(+)-3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano[3,2-g]chromen-3-yl-ester, inhibits ovalbumin-induced lung inflammation in a mouse model of asthma.
    Yang EJ; Song GY; Lee JS; Yun CY; Kim IS
    Biol Pharm Bull; 2009 Mar; 32(3):444-9. PubMed ID: 19252293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
    Lin Y; Ahmed W; He M; Xiang X; Tang R; Cui ZN
    Eur J Med Chem; 2020 Dec; 207():112795. PubMed ID: 33002845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.
    Kawasaki M; Fusano A; Nigo T; Nakamura S; Ito MN; Teranishi Y; Matsumoto S; Toda H; Nomura N; Sumiyoshi T
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2689-92. PubMed ID: 24794103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.
    De Savi C; Cox RJ; Warner DJ; Cook AR; Dickinson MR; McDonough A; Morrill LC; Parker B; Andrews G; Young SS; Gilmour PS; Riley R; Dearman MS
    J Med Chem; 2014 Jun; 57(11):4661-76. PubMed ID: 24785301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors.
    Nunes IK; de Souza ET; Cardozo SV; Carvalho VF; Romeiro NC; Silva PM; Martins MA; Barreiro EJ; Lima LM
    PLoS One; 2016; 11(10):e0162895. PubMed ID: 27695125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel imidazophenoxazine-4-sulfonamides: their synthesis and evaluation as potential inhibitors of PDE4.
    Reddy SV; Rao GM; Kumar BV; Meda CL; Deora GS; Kumar KS; Parsa KV; Pal M
    Bioorg Med Chem; 2013 Apr; 21(7):1952-63. PubMed ID: 23415088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
    Sharma H; Lather V; Grewal AS; Pandita D
    Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.
    Singh D; Leaker B; Boyce M; Nandeuil MA; Collarini S; Mariotti F; Santoro D; Barnes PJ
    Pulm Pharmacol Ther; 2016 Oct; 40():1-6. PubMed ID: 27373438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
    Singh D; Lea S; Mathioudakis AG
    Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.